Immunovant, Inc.IMVTEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Deep AnalysisCompare

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.